TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20473745

Group type: EXPERIMENTAL
Intervention: Shenmai Injection (SMI) given to the observation group for 14 days along with basic treatment including polarized liquid therapy.
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group received basic treatment including polarized liquid therapy without SMI.
Number of subjects: 64
Study: 18712038

Group type: EXPERIMENTAL
Intervention: Telmisartan 40 mg once daily for 12 months
Number of subjects: 30

Group type: COMPARATOR
Intervention: Amlodipine 5 mg once daily for 12 months
Number of subjects: 30
Study: 15969859

Group type: EXPERIMENTAL
Intervention: Epoetin alfa
Number of subjects: 375

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 375
Study: 12874080

Group type: EXPERIMENTAL
Intervention: Short-course clindamycin (3 doses)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Long-course clindamycin (15 doses)
Number of subjects: 74
Study: 10477009

Group type: EXPERIMENTAL
Intervention: Breast-conserving therapy (BCT)
Number of subjects: 66
Study: 8945129

Group type: EXPERIMENTAL
Intervention: Daily vaginal douche for one day (Group A)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Daily vaginal douche for four days (Group B)
Number of subjects: 31
Study: 1901543

Group type: EXPERIMENTAL
Intervention: Chloramphenicol
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Ampicillin
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Cefotaxime
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 200
Study: 7072756

Group type: EXPERIMENTAL
Intervention: Sucrose solution
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control preparation (starch or saccharin)
Number of subjects: 9
Study: 30312423

Group type: EXPERIMENTAL
Intervention: Fat mass
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Waist circumference
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: HOMA-IR
Number of subjects: 240
Study: 28315479

Group type: EXPERIMENTAL
Intervention: personalized pharmaceutical and psychological education
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: personalized pharmaceutical and general education
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo pharmaceutical and psychological education
Number of subjects: 0
Study: 26364968

Group type: COMPARATOR
Intervention: Propofol-fentanyl (PF)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine-ketamine (DK)
Number of subjects: 83
Study: 24372314

Group type: EXPERIMENTAL
Intervention: Intra-articular irrigation and betamethasone injection (group I)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conservative treatment and rigid maxillomandibular fixation (MMF) (group II)
Number of subjects: 30
Study: 22024157

Group type: EXPERIMENTAL
Intervention: Single-shot wound infiltration of 20mL of ropivacaine 7.5mg/mL (Group R; n=56)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Single-shot wound infiltration of 20mL of saline solution (Group T; n=44)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups (R and T)
Number of subjects: 100
Study: 19681340

Group type: EXPERIMENTAL
Intervention: Cryosurgery
Number of subjects: 20

Group type: COMPARATOR
Intervention: Trichloroacetic acid (TCA) 100% peels
Number of subjects: 20
Study: 17172557

Group type: EXPERIMENTAL
Intervention: Treadmill inclination at 6%
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Treadmill inclination at 8%
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Treadmill inclination (0%-8%)
Number of subjects: 12
Study: 15851340

Group type: EXPERIMENTAL
Intervention: Biphasic rectilinear (BR) waveform shocks (50, 75, 100, 120, 150, 200 J)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Biphasic truncated exponential (BTE) waveform shocks (50, 70, 100, 125, 150, 200, 300, 360 J)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Comparison of BR and BTE waveforms
Number of subjects: 188
Study: 19728887

Group type: EXPERIMENTAL
Intervention: 500 mcg darbepoetin alfa every three weeks (Q3W)
Number of subjects: 705

Group type: COMPARATOR
Intervention: 2.25 mcg/kg darbepoetin alfa weekly (QW)
Number of subjects: 705
Study: 10598754

Group type: EXPERIMENTAL
Intervention: Chemical SPF 4 sunscreen
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Chemical SPF 10 sunscreen
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Physical SPF 10 sunscreen
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Thin layer of chemical SPF 10 sunscreen
Number of subjects: 17

Group type: COMPARATOR
Intervention: Irradiated unprotected skin
Number of subjects: 17
Study: 7562168

Group type: EXPERIMENTAL
Intervention: Quiet tidal breathing (end-tidal inspiration and end-tidal expiration)
Number of subjects: 49
Study: 1745709

Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cocaine 20 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cocaine 40 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6192751

Group type: EXPERIMENTAL
Intervention: CAVB (Cyclophosphamide, Adriamycin, Vincristine, Bleomycin) scheduled regime
Number of subjects: 54

Group type: COMPARATOR
Intervention: CAVB (Cyclophosphamide, Adriamycin, Vincristine, Bleomycin) unscheduled regime
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: CAVBP (CAVB with Cis-platinum)
Number of subjects: 54
Study: 31444692

Group type: EXPERIMENTAL
Intervention: TheraBracelet (real stimulation month)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Sham month (control)
Number of subjects: 25
Study: 29398233

Group type: EXPERIMENTAL
Intervention: 0.01% superdiluted atropine eyedrops
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group without treatment
Number of subjects: 200
Study: 24330320

Group type: EXPERIMENTAL
Intervention: Peer-led group education program
Number of subjects: 80

Group type: COMPARATOR
Intervention: Educational booklet only (Control)
Number of subjects: 80
Study: 24946226

Group type: EXPERIMENTAL
Intervention: Topical sucralfate mouthwash
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Topical clindamycin mouthwash
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo (cellulose)
Number of subjects: 101
Study: 22832261

Group type: EXPERIMENTAL
Intervention: Intradermal low-antigen-content split inactivated vaccine
Number of subjects: 54

Group type: COMPARATOR
Intervention: Intramuscular standard-dose inactivated split vaccine
Number of subjects: 54
Study: 19582577

Group type: EXPERIMENTAL
Intervention: Patient self-administered abdominal pressure
Number of subjects: 103

Group type: COMPARATOR
Intervention: Assistant-administered abdominal pressure
Number of subjects: 103
Study: 18989229

Group type: EXPERIMENTAL
Intervention: Strong IFN‐gamma responses to HCMV (>500 spot‐forming units)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Weak IFN‐gamma responses to HCMV (<500 spot‐forming units)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Strong IFN‐gamma responses to HCMV
Number of subjects: 75
Study: 16242586

Group type: EXPERIMENTAL
Intervention: Extended advice (clinician advice + telephone-based counseling)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Brief advice (clinician advice alone)
Number of subjects: 100
Study: 12117739

Group type: EXPERIMENTAL
Intervention: Candesartan (16 mg/d)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Felodipine (5 mg/d)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 9470315

Group type: EXPERIMENTAL
Intervention: Captopril 50 mg (Group 2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Captopril 100 mg (Group 3)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (Group 1)
Number of subjects: 0
Study: 7649582

Group type: EXPERIMENTAL
Intervention: Human amylin infusion
Number of subjects: 9
Study: 2709497

Group type: EXPERIMENTAL
Intervention: Lidocaine combined with cocaine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lidocaine alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Repeat examinations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Older patients
Number of subjects: 0
Study: 778890

Group type: EXPERIMENTAL
Intervention: Progressive relaxation training
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3

Group type: COMPARATOR
Intervention: No-treatment
Number of subjects: 3
Study: 31317279

Group type: COMPARATOR
Intervention: Placebo in advanced PD patients
Number of subjects: 0
Study: 28074802

Group type: EXPERIMENTAL
Intervention: Goal-directed therapy (GDT)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Control group (conventional hemodynamic management)
Number of subjects: 163
Study: 24935686

Group type: EXPERIMENTAL
Intervention: 0.5 g of ethanol/kilogram bodyweight, taken orally immediately before lights off
Number of subjects: 26
Study: 23743717

Group type: EXPERIMENTAL
Intervention: Acute aerobic exercise
Number of subjects: 30

Group type: COMPARATOR
Intervention: Rest condition
Number of subjects: 30
Study: 21529370

Group type: EXPERIMENTAL
Intervention: Depression Recognition and Treatment package (DepReT-Stroke) in addition to treatment as usual (TAU)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 126
Study: 19195498

Group type: EXPERIMENTAL
Intervention: rosuvastatin 10 mg once a day
Number of subjects: 30

Group type: COMPARATOR
Intervention: atorvastatin 40 mg once a day
Number of subjects: 30
Study: 16522919

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 736

Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 736
Study: 12958326

Group type: EXPERIMENTAL
Intervention: Transient ischemic attack (TIA)
Number of subjects: 498

Group type: COMPARATOR
Intervention: No TIA
Number of subjects: 498
Study: 11599826

Group type: EXPERIMENTAL
Intervention: Preconditioned group (n = 17)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (n = 18)
Number of subjects: 35
Study: 9485974

Group type: EXPERIMENTAL
Intervention: T-bag
Number of subjects: 30

Group type: COMPARATOR
Intervention: T-piece
Number of subjects: 30
Study: 7892024

Group type: EXPERIMENTAL
Intervention: Epidural morphine (EM) 4 mg administered via the L2-L3 intervertebral space
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Epidural morphine (EM) 4 mg administered pre-trauma
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 2
Study: 3287226

Group type: EXPERIMENTAL
Intervention: Defibrotide at a dose of 400 mg b.i.d. i.v. in 50 ml phleboclysis in 5 minutes (n = 108)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Calcium heparin at a dose of 5000 IU t.i.d. subcutaneously (n = 103)
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Defibrotide
Number of subjects: 211

Group type: COMPARATOR
Intervention: Calcium heparin
Number of subjects: 211
Study: 31898965

Group type: EXPERIMENTAL
Intervention: WBC count at baseline (per 1 × 10^9/L increase)
Number of subjects: 14231
Study: 30501618

Group type: COMPARATOR
Intervention: 1 dose of intravenous dexamethasone and 1 dose of normal saline (Group B)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 2 doses of intravenous dexamethasone (Group C)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Normal saline only (Group A)
Number of subjects: 150
Study: 27941394

Group type: EXPERIMENTAL
Intervention: Fozivudine (FZD) 800 mg o.d., 600 mg b.i.d., 1200 mg o.d.
Number of subjects: 119

Group type: COMPARATOR
Intervention: Zidovudine (ZDV) 300 mg b.i.d.
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Fozivudine (FZD)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Zidovudine (ZDV)
Number of subjects: 119
Study: 26567086

Group type: EXPERIMENTAL
Intervention: Intact restorations
Number of subjects: 649

Group type: COMPARATOR
Intervention: Defective restorations
Number of subjects: 649
Study: 23827107

Group type: EXPERIMENTAL
Intervention: Injection/oral itraconazole
Number of subjects: 112

Group type: COMPARATOR
Intervention: Oral itraconazole
Number of subjects: 112
Study: 21838094

Group type: EXPERIMENTAL
Intervention: Total laryngectomy
Number of subjects: 20
Study: 19796721

Group type: EXPERIMENTAL
Intervention: Live attenuated influenza vaccine (LAIV)
Number of subjects: 3242

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3242
Study: 16631274

Group type: EXPERIMENTAL
Intervention: Gliclazide (n=21)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Glibenclamide (n=20)
Number of subjects: 41
Study: 15571210

Group type: EXPERIMENTAL
Intervention: Bumetanide 4 mg/day
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 5'N‐ethylcarboxamido‐adenosine (NECA)
Number of subjects: 70
Study: 11731753

Group type: EXPERIMENTAL
Intervention: Sevoflurane anesthesia
Number of subjects: 180

Group type: COMPARATOR
Intervention: Propofol anesthesia
Number of subjects: 180
Study: 9004053

Group type: EXPERIMENTAL
Intervention: Lithium augmentation
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 9114914

Group type: EXPERIMENTAL
Intervention: Pravastatin (20 mg) and Digoxin (0.2 mg) in combination
Number of subjects: 18

Group type: COMPARATOR
Intervention: Pravastatin (20 mg) alone
Number of subjects: 18
Study: 3678415

Group type: EXPERIMENTAL
Intervention: Inspirease (IP)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Aerochamber (AC)
Number of subjects: 13

Group type: COMPARATOR
Intervention: metered dose inhaler (MDI)
Number of subjects: 13
Study: 29475008

Group type: EXPERIMENTAL
Intervention: rosuvastatin 20 mg/day (R20)
Number of subjects: 44

Group type: COMPARATOR
Intervention: atorvastatin 10 mg/day combined with ezetimibe 10 mg/day (A10 + E10)
Number of subjects: 44
Study: 27496680

Group type: EXPERIMENTAL
Intervention: Thalidomide (200 mg daily)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Thalidomide
Number of subjects: 25
Study: 25694918

Group type: EXPERIMENTAL
Intervention: Mobi-C Cervical Total Disc Replacement (TDR)
Number of subjects: 245

Group type: COMPARATOR
Intervention: Anterior Cervical Discectomy and Fusion (ACDF)
Number of subjects: 245
Study: 22966146

Group type: EXPERIMENTAL
Intervention: AZD9056 400 mg/day
Number of subjects: 385

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: AZD9056 (all doses)
Number of subjects: 385
Study: 20808331

Group type: EXPERIMENTAL
Intervention: Milk formulation containing 975 mg of milk sphingolipids (SL)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control formulation lacking polar milk lipids
Number of subjects: 18
Study: 18454864

Group type: EXPERIMENTAL
Intervention: Intravenous antibiotics for 8 days
Number of subjects: 58

Group type: COMPARATOR
Intervention: No antibiotics
Number of subjects: 58
Study: 16162706

Group type: COMPARATOR
Intervention: General Exercise Program (GEP)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Individually Targeted Exercise Program (ITEP)
Number of subjects: 180
Study: 14551179

Group type: EXPERIMENTAL
Intervention: Ragaglitazar 4 mg for 21 days in patients with type 2 diabetes
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Ragaglitazar (various doses 0.5-16 mg) for healthy subjects
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Ragaglitazar (various doses) in healthy subjects
Number of subjects: 4
Study: 11310905

Group type: EXPERIMENTAL
Intervention: Propofol with EDTA
Number of subjects: 85

Group type: COMPARATOR
Intervention: Propofol without EDTA
Number of subjects: 85
Study: 8792760

Group type: EXPERIMENTAL
Intervention: antidepressant treatment (amitriptyline hydrochloride, fluoxetine hydrochloride, toloxatone)
Number of subjects: 30

Group type: COMPARATOR
Intervention: nonresponders (no treatment specified)
Number of subjects: 30
Study: 8101534

Group type: EXPERIMENTAL
Intervention: Topical levocabastine
Number of subjects: 115

Group type: COMPARATOR
Intervention: Orally administered terfenadine
Number of subjects: 115
Study: 3299393

Group type: EXPERIMENTAL
Intervention: 1% hydrocortisone plus 0.5% potassium hydroxyquinoline sulphate cream
Number of subjects: 119

Group type: COMPARATOR
Intervention: 1% hydrocortisone plus 2% miconazole nitrate cream
Number of subjects: 119
Study: 29076609

Group type: EXPERIMENTAL
Intervention: Home-based lower limb resistance training (LLRT)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Routine pulmonary rehabilitation (PR) guidance + Home-based LLRT
Number of subjects: 47

Group type: COMPARATOR
Intervention: Routine pulmonary rehabilitation (PR) guidance only
Number of subjects: 47
Study: 27448679

Group type: EXPERIMENTAL
Intervention: Intravenous-to-oral solithromycin
Number of subjects: 863

Group type: COMPARATOR
Intervention: Intravenous-to-oral moxifloxacin
Number of subjects: 863
Study: 25222265

Group type: EXPERIMENTAL
Intervention: Fast Mapping (FM)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Explicit Encoding (EE)
Number of subjects: 50
Study: 22385683

Group type: EXPERIMENTAL
Intervention: FITNET
Number of subjects: 135

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 135
Study: 20845217

Group type: EXPERIMENTAL
Intervention: Small added resistance
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Moderate added resistance
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Large added resistance
Number of subjects: 10

Group type: COMPARATOR
Intervention: No added resistance
Number of subjects: 10
Study: 18955830

Group type: EXPERIMENTAL
Intervention: Metabolic syndrome (MetS) present
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Glucose intolerance
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Metabolic syndrome (MetS) in nondiabetic participants
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Metabolic syndrome (MetS) after adjustment for diabetes status
Number of subjects: 100
Study: 16459863

Group type: EXPERIMENTAL
Intervention: Hoffa's fat pad resection
Number of subjects: 68

Group type: COMPARATOR
Intervention: Hoffa's fat pad preservation
Number of subjects: 68
Study: 14512102

Group type: EXPERIMENTAL
Intervention: Higher methadone doses (more than 80 mg)
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Good quality of interpersonal relationships
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Stable employment
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Lower craving scores
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Psychopharmacological treatment associated with methadone
Number of subjects: 265

Group type: COMPARATOR
Intervention: Weekly or twice weekly methadone administration
Number of subjects: 265
Study: 10855941

Group type: EXPERIMENTAL
Intervention: Prolonged courses of steroids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cyclosporine A and cytotoxic agents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pulse methylprednisolone, azathioprine, tacrolimus, mycophenolate mofetil, combination therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Plasmapheresis
Number of subjects: 0
Study: 8695243

Group type: EXPERIMENTAL
Intervention: Serum CEA > or = 5 micrograms/l
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Serum beta HCG > or = 4 U/l
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: CA125 > or = 35 U/ml
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: CA125 > or = 350 U/ml
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Serum beta HCG > or = 4 IU/l (multivariate analysis)
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: CA125 > or = 350 U/ml (multivariate analysis)
Number of subjects: 290
Study: 1839981

Group type: EXPERIMENTAL
Intervention: Thymoxamine-HCl (120 mg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Thymoxamine-HCl (240 mg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Thymoxamine-HCl (480 mg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Thymoxamine-HCl (dose-dependent)
Number of subjects: 9
Study: 3901833

Group type: EXPERIMENTAL
Intervention: anterior rhinometry
Number of subjects: 49
Study: 31306319

Group type: EXPERIMENTAL
Intervention: Tissue adhesive (2-octyl cyanoacrylate)
Number of subjects: 504

Group type: COMPARATOR
Intervention: Sterile strips
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Tissue adhesive
Number of subjects: 504
Study: 30048916

Group type: EXPERIMENTAL
Intervention: Nurse-led structured advance care planning programme
Number of subjects: 230

Group type: COMPARATOR
Intervention: Self-care management as attention control
Number of subjects: 230
Study: 25192967

Group type: EXPERIMENTAL
Intervention: Postoperative worst pain ratings (day 1 to day 4)
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Mean oral morphine intake
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Associations with postoperative worst pain ratings
Number of subjects: 416
Study: 25085736

Group type: EXPERIMENTAL
Intervention: Dual computer monitors
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (no dual monitors)
Number of subjects: 54
Study: 22987468

Group type: EXPERIMENTAL
Intervention: Cancer pain self-management intervention
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Individually tailored counselling by a professional
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Previous experiences of patients
Number of subjects: 8
Study: 20200939

Group type: EXPERIMENTAL
Intervention: Ibuprofen (400 mg) before exercise
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Placebo before, ibuprofen after
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo before and after
Number of subjects: 73
Study: 17881719

Group type: EXPERIMENTAL
Intervention: CEP-1347 10 mg BID
Number of subjects: 806

Group type: EXPERIMENTAL
Intervention: CEP-1347 25 mg BID
Number of subjects: 806

Group type: EXPERIMENTAL
Intervention: CEP-1347 50 mg BID
Number of subjects: 806

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 806
Study: 15674304

Group type: EXPERIMENTAL
Intervention: Red wine (males: 300 ml/day, 38.3 g alcohol/day; females: 200 ml/day, 25.5 g alcohol/day)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Water + red grape extract tablets (wine-equivalent dose)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Water + red grape extract tablets (half dose)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Water + placebo tablets
Number of subjects: 69
Study: 12003977

Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg once daily for 5 days
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (non-infected nasal polyps)
Number of subjects: 48